Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.0001 USD | -.--% | -.--% | +9,900.00% |
2023 | Nabriva Therapeutics plc Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 | CI |
2023 | Nabriva Therapeutics plc(OTCPK:NBRV.F) dropped from NASDAQ Composite Index | CI |
Business Summary
Number of employees: 39
Sales per Business
USD in Million | 2021 | Weight | 2022 | Weight | Delta |
---|---|---|---|---|---|
Novel Anti-infective Agents
100.0
%
| 29 | 100.0 % | 37 | 100.0 % | +27.82% |
Sales per region
USD in Million | 2021 | Weight | 2022 | Weight | Delta |
---|---|---|---|---|---|
Austria, Ireland, and United States
100.0
%
| 29 | 100.0 % | 37 | 100.0 % | +27.82% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
H. Hogan
CEO | Chief Executive Officer | 61 | 23-07-06 |
Dave Maggio
DFI | Director of Finance/CFO | 64 | 23-06-29 |
Steven Gelone
BRD | Director/Board Member | 56 | 17-06-22 |
Director/Board Member | 69 | 18-07-23 | |
Kim Anderson
IRC | Investor Relations Contact | - | - |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Daniel Burgess
CHM | Chairman | 62 | 17-06-22 |
Director/Board Member | 69 | 18-07-23 | |
Stephen Webster
BRD | Director/Board Member | 63 | 16-07-31 |
Charles Rowland
BRD | Director/Board Member | 65 | 14-12-31 |
Steven Gelone
BRD | Director/Board Member | 56 | 17-06-22 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 3,230,837 | 3,200,138 ( 99.05 %) | 0 | 99.05 % |
Company contact information
Sector
1st Jan change | Capi. | |
---|---|---|
+9,900.00% | 323 | |
-1.43% | 104B | |
+7.15% | 97.47B | |
+5.71% | 22.25B | |
-12.73% | 21.68B | |
-9.70% | 18.2B | |
-39.98% | 17.02B | |
-10.50% | 16.36B | |
+7.45% | 14.39B | |
+37.50% | 12.37B |
- Stock Market
- Equities
- NBRVF Stock
- Company Nabriva Therapeutics plc